AstraZeneca’s Covid-19 antibody drug heads into advanced trials
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SUNDAY, MAY 22, 2022
SUNDAY, MAY 22, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
AstraZeneca’s Covid-19 antibody drug heads into advanced trials

Coronavirus chronicle

TBS Report
12 October, 2020, 05:00 pm
Last modified: 12 October, 2020, 06:33 pm

Related News

  • AstraZeneca Covid drug neutralises Omicron sub-variants in study
  • Short AstraZeneca shelf life complicates Covid vaccine rollout to world's poorest
  • New data finds AstraZeneca booster generates higher antibodies against Omicron
  • Nigeria destroys 1 mln donated AstraZeneca vaccines with short shelf life
  • Another 7 lakh Covid-19 vaccines arrive in Bangladesh from Japan

AstraZeneca’s Covid-19 antibody drug heads into advanced trials

AstraZeneca is one of a number of companies exploring monoclonal antibodies as a way to prevent and treat Covid-19, which could be key for high-risk populations who may not respond well to a vaccine

TBS Report
12 October, 2020, 05:00 pm
Last modified: 12 October, 2020, 06:33 pm
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo

British-Swedish drugmaker AstraZeneca has started late-stage trials for an antibody medicine against Covid-19 with a large investment from the US, after President Donald Trump credited a similar therapy with aiding his recovery.

Two trials for more than 6,000 people are starting in the next few weeks looking at prevention, with plans for a further 4,000 adults to test the antibody medicine as a treatment, Astra said in a statement, reports Bloomberg.

The drug will be assessed for its ability to avoid infections for as much as a year in some people and as a pre-emptive medicine once patients have been exposed to the virus in others.

AstraZeneca is one of a number of companies exploring monoclonal antibodies as a way to prevent and treat Covid-19, which could be key for high-risk populations who may not respond well to a vaccine.

The US has already secured hundreds of thousands of doses of the experimental treatments.

Eli Lilly & Co. and Regeneron Pharmaceuticals Inc. last week asked the US Food and Drug Administration for emergency-use authorizations but are yet received clearance.

US President Donald Trump has said Regeneron's antibody cocktail was key to his apparent recovery from coronavirus.

Early data from both Eli Lilly and Regeneron suggest the medicines are effective in keeping infected people out of the hospital.

GlaxoSmithKline Plc and Vir Biotechnology Inc. also started advanced tests on a possible antibody treatment last week.

AstraZeneca has agreed to supply as many as 100,000 doses to the US by the end of 2020, with an option for the country to purchase one million additional doses in 2021.

 The US previously gave the British pharmaceutical company $25 million for the discovery and evaluation of the monoclonal antibodies, and the phase I trial started in August.

The company's long-acting antibody "has the potential to provide immediate and long-lasting effect in both preventing and treating Covid-19 infections," Chief Executive Officer Pascal Soriot said in a statement released Friday.

Top News

AstraZeneca / Covid-19 Antibody Test

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Project delays: The Sinohydro style 
    Project delays: The Sinohydro style 
  • Photo: TBS
    37,000 BO account holders sell all shares in 11 days
  • Photo: Reuters
    Monkeypox: Govt puts ports on alert 

MOST VIEWED

  • People wearing protective face masks walk on a street, following new cases of the coronavirus disease (Covid-19), in Shanghai, China August 25, 2021. REUTERS/Aly Song
    Shanghai district to require all shops to shut, residents to stay home
  • Photo: Courtesy
    Covax calls for urgent action to close vaccine equity gap
  • Photo: BSS/AFP
    Covax calls for urgent action to close vaccine equity gap
  • Photo: Collected
    Thousands of Covid-negative Beijing residents sent to quarantine
  • A man checks phone at Lujiazui financial district in Pudong, Shanghai, China March 14, 2019. Photo :Reuters
    Shanghai inches towards Covid lockdown exit, Beijing plays defence
  • North Korean leader Kim Jong Un delivers opening remarks during the 2nd Conference of Secretaries of Primary Committees of the Workers' Party of Korea (WPK), in this photo released on February 27, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS/File Photo
    N Korea reports over 200,000 fever cases for 5th day amid Covid wave

Related News

  • AstraZeneca Covid drug neutralises Omicron sub-variants in study
  • Short AstraZeneca shelf life complicates Covid vaccine rollout to world's poorest
  • New data finds AstraZeneca booster generates higher antibodies against Omicron
  • Nigeria destroys 1 mln donated AstraZeneca vaccines with short shelf life
  • Another 7 lakh Covid-19 vaccines arrive in Bangladesh from Japan

Features

The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters

Eco-fascism: The greenwashing of the far right

14h | Panorama
Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque

Green-backed Heron: Nothing but a prayer to catch a fish  

16h | Panorama
Illustration: TBS

‘High logistics cost weakens Bangladesh’s competitiveness’

18h | Panorama
Every morning is a new beginning for all

Seashore

19h | In Focus

More Videos from TBS

Wheat prices double in India

Wheat prices double in India

8h | Videos
Is Washington-Moscow agreement possible?

Is Washington-Moscow agreement possible?

8h | Videos
Pigeon exhibition for the first time in Gazipur

Pigeon exhibition for the first time in Gazipur

13h | Videos
Photo: TBS

US Congress to hold first public UFO panel

15h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The reception is a volumetric box-shaped room that has two glass walls on both the front and back ends and the other two walls are adorned with interior plants, wood and aluminium screens. Photo: Noor-A-Alam
Habitat

The United House: Living and working inside nature

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab